Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)

References

• Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–553. doi:10.3324/haematol.2019.232132
   PubMed Web of Science ®Google Scholar
• Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252–261. doi:10.1160/TH16-06-0444
   PubMed Web of Science ®Google Scholar
• Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117(9):1705–1713. doi:10.1160/TH17-03-0166
   PubMed Web of Science ®Google Scholar
• Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glyco-PEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11(4):670–678. doi:10.1111/jth.12161
   PubMed Web of Science ®Google Scholar
• Giangrande P, Abdul Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder 2. J Thromb Haemost. 2020;18(Suppl 1):5–14. doi:10.1111/jth.14959.
   Web of Science ®Google Scholar
• Šaulytė Trakymienė S, Economou M, Kenet G, Landorph A, Shen C, Kearney S. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: final results from pathfinder 5. J Thromb Haemost. 2020;18(Suppl 1):15–25. doi:10.1111/jth.15036
   PubMed Web of Science ®Google Scholar
• Hampton K, Chowdary P, Dunkley S, et al. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. Haemophilia. 2017;23(5):689–696. doi:10.1111/hae.13246
   Web of Science ®Google Scholar
• Tosetto A, Neff A, Lentz SR, et al. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: full data set from the pathfinder 3 and 5 phase III trials. Haemophilia. 2020;26(3):450–458. doi:10.1111/hae.13980
   Web of Science ®Google Scholar
• Matsushita T, Mangles S. An overview of the pathfinder clinical trials program: long‐term efficacy and safety of N8‐GP in patients with hemophilia A. J Thromb Haemost. 2020;18(Suppl 1):26–33. doi:10.1111/jth.14958
   Web of Science ®Google Scholar
• Meunier S, D’oiron R, Chambost H, Dolimier E, Guillet B. ORTHem 15-25 Study Group. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25). Thromb Res. 2017;151:17–22. doi:10.1016/j.thromres.2016.12.023
   Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939. doi:10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• Chowdary P, Carcao M, Holme PA, et al. Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A. Res Pract Thromb Haemost. 2019;3(3):542–554. doi:10.1002/rth2.12220
   Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. Br J Haematol. 2020;190(5):684–695. doi:10.1111/bjh.16704
   Web of Science ®Google Scholar
• Chowdary P. Extended half-life recombinant products in haemophilia clinical practice – expectations, opportunities and challenges. Thromb Res. 2020;196:609–617. doi:10.1016/j.thromres.2019.12.012
   Web of Science ®Google Scholar
• Mahlangu JN, Ragni M, Gupta N, et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016;116(1):1–8. doi:10.1160/TH15-10-0780
   PubMed Web of Science ®Google Scholar
• Gruppo R, López-Fernández M-F, Wynn TT, Engl W, Sharkhawy M, Tangada S. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial. Haemophilia. 2019;25(5):773–781. doi:10.1111/hae.13807
   PubMed Web of Science ®Google Scholar
• Santagostino E, Lalezari S, Reding MT, et al. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: results of the PROTECT VIII clinical trial. Thromb Res. 2019;183:13–19. doi:10.1016/j.thromres.2019.08.023
   PubMed Web of Science ®Google Scholar
• Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9(9):295–308. doi:10.1177/2040620718796429
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Cortesi PA, Di Minno MND, Sanò M, Mantovani LG, Di Minno G. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A. Haemophilia. 2021;27(4):e422–e433. doi:10.1111/hae.14313
   Web of Science ®Google Scholar
• Brennan Y, Parikh S, McRae S, Tran H. The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors’ Organisation. Haemophilia. 2020;26(3):529–535. doi:10.1111/hae.13970
   PubMed Web of Science ®Google Scholar